AU2021365394A1 - Microrna-29 compounds, compositions and uses in therapy - Google Patents

Microrna-29 compounds, compositions and uses in therapy Download PDF

Info

Publication number
AU2021365394A1
AU2021365394A1 AU2021365394A AU2021365394A AU2021365394A1 AU 2021365394 A1 AU2021365394 A1 AU 2021365394A1 AU 2021365394 A AU2021365394 A AU 2021365394A AU 2021365394 A AU2021365394 A AU 2021365394A AU 2021365394 A1 AU2021365394 A1 AU 2021365394A1
Authority
AU
Australia
Prior art keywords
mir
compound
salt
dose
cwt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021365394A
Other languages
English (en)
Other versions
AU2021365394A9 (en
Inventor
Derek Stewart GILCHRIST
Neal Lindsay MILLAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Causeway Therapeutics Ltd
Original Assignee
Causeway Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Causeway Therapeutics Ltd filed Critical Causeway Therapeutics Ltd
Publication of AU2021365394A1 publication Critical patent/AU2021365394A1/en
Publication of AU2021365394A9 publication Critical patent/AU2021365394A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021365394A 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy Pending AU2021365394A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2016863.9 2020-10-23
GBGB2016863.9A GB202016863D0 (en) 2020-10-23 2020-10-23 Microrna-29 compounds, compositions and uses in therapy
PCT/EP2021/079580 WO2022084561A2 (en) 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy

Publications (2)

Publication Number Publication Date
AU2021365394A1 true AU2021365394A1 (en) 2023-06-08
AU2021365394A9 AU2021365394A9 (en) 2024-09-26

Family

ID=73726994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021365394A Pending AU2021365394A1 (en) 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy

Country Status (9)

Country Link
US (1) US20240390410A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232580A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023547274A (cg-RX-API-DMAC7.html)
KR (1) KR20230088810A (cg-RX-API-DMAC7.html)
CN (1) CN116744942A (cg-RX-API-DMAC7.html)
AU (1) AU2021365394A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195977A1 (cg-RX-API-DMAC7.html)
GB (1) GB202016863D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022084561A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4634386A4 (en) * 2022-12-16 2026-08-12 Mirscience Therapeutics Servicos De Pesquisa E Desenvolvimento Ltda Antisense oligonucleotide analogues of MIR-29 and their uses
AU2023445724A1 (en) * 2023-04-28 2025-11-06 Causeway Therapeutics Limited Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400598D0 (en) 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
DK3149172T3 (en) * 2014-05-29 2018-08-20 Quark Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE PREVENTION OF ISKEMIC REPERFUSION LESSON IN BODIES
CN107108685B (zh) * 2014-09-08 2020-10-20 米拉根医疗股份有限公司 miR-29模拟物及其用途
GB201503967D0 (en) * 2015-03-09 2015-04-22 Univ Glasgow Biocompatible implants for use in tendon therapy
WO2020181130A2 (en) * 2019-03-05 2020-09-10 MiRagen Therapeutics, Inc. Polynucleotide conjugates and uses thereof

Also Published As

Publication number Publication date
US20240390410A1 (en) 2024-11-28
KR20230088810A (ko) 2023-06-20
EP4232580A2 (en) 2023-08-30
CA3195977A1 (en) 2022-04-28
CN116744942A (zh) 2023-09-12
WO2022084561A3 (en) 2022-06-02
JP2023547274A (ja) 2023-11-09
WO2022084561A2 (en) 2022-04-28
GB202016863D0 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
US20230109457A1 (en) Use of cdk9 inhibitors to reduce cartilage degradation
TWI477273B (zh) 低頻率格拉替雷(glatiramer)醋酸鹽之治療
JP2020073479A (ja) アルポート症候群の処置方法
JP7133553B2 (ja) 多発性嚢胞腎疾患の処置のための修飾オリゴヌクレオチド
JP2021185149A (ja) アポリポタンパク質(a)発現の調節
US20240390410A1 (en) Microrna-29 compounds, compositions and uses in therapy
CN120957731A (zh) 用于治疗多囊肾病的修饰的寡核苷酸
US20260049310A1 (en) Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)
JP7105775B2 (ja) 多発性嚢胞腎疾患の処置のための方法
US20240360446A1 (en) Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions
US20200318113A1 (en) Polynucleotide conjugates and uses thereof
WO2022178146A1 (en) Compounds and methods for reducing nlrp3 expression
JP7514563B2 (ja) オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物
KR20260061479A (ko) 식도 협착 억제제
CN115381950B (zh) Rab 35或其下游调控分子在治疗骨折后慢性疼痛中的应用
CN115252787B (zh) Zip7在抑制阿片类药物诱发的痛觉过敏中的应用
RIVAROXABAN et al. SUSTAINED EFFICACY OF INTRA-ARTICULAR FX006 IN A RAT MODEL OF OSTEOARTHRITIS
Rodriguez-Elizalde et al. Compliance with thromboprophylaxis using an oral factor Xa inhibitor rivaroxaban after total hip and knee arthroplasty. Is oral therapy better? An examination of the non-adherence rate of rivaroxaban

Legal Events

Date Code Title Description
SREP Specification republished